ATEM Capital Information

ATEM Capital is a New York life-sciences investment firm. We back breakthrough bioplatforms, advanced medical devices, next-generation molecular diagnostics, and AI-driven digital health, and we take companies from lab to IPO. We syndicate with firms including OrbiMed, Pontifax, Leaps by Bayer, and Northpond. Priority areas: oncology, autoimmune, CNS, antivirals and antibiotics, women’s health, and industrial biotechnology. The Advisory Board includes veterans of Celgene, AstraZeneca, GSK, Teva, and former senior FDA and venture executives. Recent investments include Triumvira Immunologics, Amolyt Pharma (acquired by AstraZeneca), and Iridia.

Website	http://www.atemcap.com
Revenue	$5.1 million
Employees	7 (2 on RocketReach)
Address	445 Park Ave, New York, New York 10022, US
Phone	+1 905-483-2874
Technologies	JavaScript , HTML , G Suite +8 more (view full list)
Industry	Investment Management, Finance General, Finance
Web Rank	30 Million
Keywords	Financial Markets, Health Tech Investing, Life Sciences Fund, Emerging Markets Investing, Evergreen Fund, Biotech Fund, Investment Fund Management, Alternative Investments, Private Equity Fund, Venture Capital Fund, Global Investments, Financial Services, Investment Management, Portfolio Management, Asset Management, Wealth Management
Competitors	The Blackstone Group, KKR, Apollo Global Management, Inc., The Carlyle Group, TPG, Warburg Pincus LLC, Bain Capital, Vista Equity Partners, Advent International, Hellman & Friedman +33 more (view full list)
SIC	SIC Code 679 Companies, SIC Code 67 Companies
NAICS	NAICS Code 5239 Companies, NAICS Code 523 Companies, NAICS Code 52 Companies